IM Cannabis: 66% Revenue Growth In Germany, Narrows EBITDA Loss In Q3
IM Cannabis: 66% Revenue Growth In Germany, Narrows EBITDA Loss In Q3
International medical cannabis company IM Cannabis Corp. (NASDAQ:IMCC) (CSE:IMCC) announced its financial results on Thursday for the third quarter ended Sept. 30, 2024.
国际医疗大麻公司Im Cannabis Corp.(纳斯达克:IMCC)(cse:IMCC)于周四发布了截至2024年9月30日第三季度的财务业绩。
The company reported revenue from Germany grew 66% year-over-year, reaching CA$5.8 million ($4.1 million).
该公司的来自德国的营业收入同比增长66%，达到了580万加元（410万美元）。
"While the 66% growth we delivered in Germany, to reach $5.8M this quarter is a highlight, we spent the quarter focused on building a solid foundation for 2025," said CEO Oren Shuster. "Our goal was to build a strong, consistent supply chain, along with a laser focus on how to improve the efficiency and accuracy of how we use our resources. I believe that the foundation we built this quarter will be the basis we will use to deliver in 2025."
“虽然我们在德国实现了66%的增长，本季度达到了580万加元，这是一大亮点，但我们专注于为2025年打下坚实基础，”首席执行官奥伦·舒斯特表示。“我们的目标是建立一个强大而一致的供应链，并专注于如何提高我们资源的使用效率和准确性。我相信，我们本季度建立的基础将是我们在2025年交付的基础。”
Read Also: IM Cannabis Soars: German Sales Surge 200% In First 3 Months Post-Legalization, Q2 Revenue Up 12% YoY
另请阅读：Im Cannabis股价飙升：德国销售在合法化后头三个月激增200%，第二季度营业收入同比增长12%
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 订阅本新闻快讯，每天免费获取Benzinga独家分析和大麻股行业及市场的最新资讯。如果您对业务认真，不容错过。在这里订阅我们的新闻简报。
Q3 Financial Highlights
Q3财务亮点
- Revenue increased by 12% year-over-year to CA$13.9 million, compared to CA$12.4 million in the third quarter of 2023.
- Gross profit was CA$3.1 million, up from CA$2.6 million in the prior year's period.
- Selling and marketing expenses dropped by 41% over the same period to CA$1.5 million.
- Total operating expenses fell by 16% year-over-year to CA$4.1 million.
- EBITDA loss narrowed by 68% over the period, from a loss of CA$1.6M in the third quarter of 2023 to a loss of CA$0.5 million in the third quarter of 2024. Adjusted EBITDA loss also improved by 82%, down to CA$0.2 million.
- The operational expense ratio improved by 25% year-over-year, falling from 40% in the third quarter of 2023 to 30% in the third quarter of 2024, reflecting improved cost management.
- Net loss narrowed to roughly CA$1 million from CA$2.1 million in the prior year's period.
- 营业收入同比增长12%，达到1390万加元，而2023年第三季度为1240万加元。
- 毛利润为310万加元，上年同期为260万加元。
- 销售和市场营销费用同比下降41%，降至150万加元。
- 总营业费用同比下降16%，降至410万加元。
- EBITDA亏损缩小68%，从2023年第三季度的160万加元亏损减少至2024年第三季度的50万加元亏损。调整后的EBITDA亏损也改善了82%，降至20万加元。
- 运营费用比例同比改善25%，从2023年第三季度的40%降至2024年第三季度的30%，反映了成本管理的改善。
- 净亏损从去年的210万加元缩小至大约100万加元。
IMCC Price Action
IMCC价格动态
IM Cannabis' shares traded 13.96% lower at $2.5339 per share at the time of writing on Thursday morning.
Im Cannabis的股份在周四上午的交易中下跌了13.96%，每股交易价格为2.5339美元。
- IM Cannabis' $1.6M Non-Brokered Private Placement Offering, Here's What Investors Need To Know
- 在大麻股的160万美元非经纪人私募股权投资中，这是投资者需要知道的内容
